Skip to main
QURE

uniQure (QURE) Stock Forecast & Price Target

uniQure (QURE) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

uniQure NV has reported an increase in SG&A expenses to $19.4 million from $11.6 million year-over-year, indicating a commitment to advancing its operational capabilities as it develops gene therapies for conditions such as Huntington's disease and cardiovascular diseases. Management maintains strong confidence in the AMT-130 data, which are considered exceptionally robust, and underscores the program's strong support within the scientific community, suggesting that regulatory challenges are more process-related than indicative of data quality. Furthermore, a favorable risk-benefit profile for AMT-130, combined with recent positive developments in ongoing trials for MTLE, underscores uniQure's pipeline potential and positions the company for future growth as it navigates the gene therapy market landscape.

Bears say

uniQure NV faces significant challenges that contribute to a negative outlook for its stock, primarily due to regulatory uncertainty surrounding its lead product AMT-130 and the subsequent withdrawal of previously indicated timelines for its Biologics License Application (BLA). The company has no revenue-generating products yet, leading to ongoing financial losses since its inception, which raises concerns regarding its long-term viability. Additionally, increasing market competition for gene therapies targeting similar indications may further constrain uniQure’s market penetration and affect potential pricing strategies.

uniQure (QURE) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About uniQure (QURE) Forecast

Analysts have given uniQure (QURE) a Buy based on their latest research and market trends.

According to 10 analysts, uniQure (QURE) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $57.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $57.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

uniQure (QURE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.